IO Biotech Reports on Phase 3 Trial Progress for Cancer Vaccine

New York, Aug. 13, 2024 (GLOBE NEWSWIRE) – IO Biotech (Nasdaq: IOBT) has announced that the interim analysis for its pivotal Phase 3 trial (IOB-013/KN-D18) of the investigational cancer vaccine IO102-IO103, in combination with Merck’s KEYTRUDA® (pembrolizumab), is anticipated in the third quarter of 2024. This trial focuses on patients with advanced melanoma, with the primary endpoint of progression-free survival (PFS) expected to be reported in the first half of 2025. The independent data monitoring committee (IDMC) will conduct a review of the interim analysis data, which is crucial for assessing the overall response rate (ORR) of the treatment. The trial aims to analyze PFS once 226 events have occurred, a milestone that the company estimates will be reached in early 2025. Enrollment is currently ongoing in a randomized cohort where patients receive either the combination treatment or pembrolizumab alone. In addition to the Phase 3 trial, IO Biotech is also conducting two Phase 2 basket trials. One trial investigates IO102-IO103 in combination with pembrolizumab as a first-line treatment for solid tumors, while the other explores its use as neoadjuvant/adjuvant therapy. Both trials are designed to further evaluate the efficacy of the cancer vaccine in various patient populations. IO Biotech emphasizes that forward-looking statements regarding trial timelines and outcomes are based on current expectations, but actual results may vary due to inherent risks and uncertainties in clinical research.